CV Lattes
ORCID
Abstract
With the advent of the immune checkpoint blockade (ICB), immunotherapy has revolutionised the way how cancer patients have been treated over the last years. Groundbreaking advances have been achieved upon cancer patient treatment with anti-PD-1 and anti-CTLA-4. However, globally, only 30-50% of cancer patients respond partially or completely to anti-PD-1 and/or anti-CTLA-4. In clear cell …